A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• Stage D prostate cancer requires effective treatment strategies.
• Androgen deprivation therapy is a cornerstone of treatment.
• Anandron (Anandron) is an anti-androgen medication.

Purpose of the Study:

• To evaluate the efficacy of Anandron (300 mg) combined with orchiectomy versus orchiectomy alone in patients with stage D prostate cancer.
• To assess the impact on subjective parameters, objective response, disease progression, and survival.

Main Methods:

• A randomized, double-blind, placebo-controlled study.
• 125 patients with stage D prostate cancer were enrolled.
• Follow-up duration was 3 years.

Main Results:

• Combined Anandron therapy showed non-significant beneficial effects on subjective parameters and objective response (NPCP criteria).
• No statistically significant improvement was observed in time-to-disease progression or survival.
• The study did not detect a significant benefit of Anandron in this patient group.

Conclusions:

• While Anandron showed some positive trends, its benefit in stage D prostate cancer when combined with orchiectomy was not statistically significant.
• Results highlight the need for identifying prognostic factors to better evaluate drug efficacy in future clinical trials.
• Further research is crucial before widespread adoption of Anandron in this setting.